V itamin D is a secosteroid prohormone synthesized in response to ultraviolet B-irradiation with pleiotropic effects reaching beyond its direct myoskeletal actions. 1 In 1981, Robert Scragg hypothesized that vitamin D might have a protective effect against cardiovascular disease. 2 Since then, several population-based studies have shown an association between reduced 25-hydroxyvitamin D levels and increased risk of both ischemic heart disease and early death; however, risk estimates vary among studies, which could be because of diversity in study size, duration of follow-up time, number of events, differences in ethnicity, different analytic measurement technique for 25-hydroxyvitamin D, and whether or not food is fortified with vitamin D in different countries. Many healthy adults are vitamin D deficient during the winter in both the United States and in European countries. 25, 26 Seen in the light of high global prevalence of both vitamin D deficiency and cardiovascular disease, the strength and magnitude of associations between reduced 25-hydroxyvitamin D and increased risks of cardiovascular disease and early death are major public health issues.
In the present study, we tested the hypothesis that reduced plasma 25-hydroxyvitamin D levels associate with increased risk of ischemic heart disease, myocardial infarction, and early death in the general population; we used the term early death rather than solely death to imply that we tested whether risk individuals died at an earlier age than reference individuals. We included 5709 women and 4410 men from the Copenhagen City Heart Study with baseline plasma 25-hydroxyvitamin D measurements and followed them for up to 29 years. Also, the associations of reduced plasma 25-hydroxyvitamin D levels with increased risk of ischemic heart disease and early death were summarized in meta-analyses, including previous and present studies.
Biochemical Analyses
Plasma 25-hydroxyvitamin D was measured using a competitive chemiluminescent immunoassay, CLIA (DiaSorin, Stillwater, MN) with intra-and interassay coefficients of variation of 10% and 11%, respectively, and a lower detection limit of 5 nmol/L. Colorimetric assays (Boehringer Mannheim, Mannheim, Germany or Konelab, Espoo, Finland) were used to measure creatinine, total cholesterol, and high-density lipoprotein cholesterol in plasma. Total cholesterol and high-density lipoprotein cholesterol were measured the same day as the blood sample was collected, and creatinine and 25-hydroxyvitamin D during January 2010 through May 2011 using samples stored at −20°C without previous thawing or exposure to sunlight.
Other Covariates
Analyses were adjusted for covariates known to influence 25-hydroxyvitamin D levels, risk of ischemic heart disease, and early death. For adjustments, covariates were on a continuous scale when possible (see Statistical Analyses). For stratification, levels were aimed for generally recommended or accepted cut points. Body mass index was expressed as weight in kilograms divided by height in meters square and coded as low (<25 kg/m 2 ) or high (≥25 kg/m 2 ). Physical activity was coded as low or high using information on physical activity during work and leisure time; low physical activity was predominantly sedentary work and/or <2 hours of leisure time physical activity per week, and high physical activity was predominantly heavy manual work and ≥2 hours of leisure time physical activity per week. Smoking status was classified as current or former/never smokers. Alcohol consumption was based on average weekly consumption of beer, wine, and liquor during the preceding month categorized into low to abstinent (<14/21 U/wk for women/men) or high (≥14/21 U/wk for women/men); 1 U alcohol ≈12 g. Hypertension was diastolic blood pressure ≥90 mm Hg (≥85 mm Hg for diabetics) and/or systolic blood pressure ≥140 mm Hg (≥135 mm Hg for diabetics) and/or use of antihypertensive medication. Diabetes mellitus was nonfasting blood glucose levels ≥11.0 mmol/L and/or insulin or other antidiabetic treatment. Estimated glomerular filtration rate 29 was low (<60 mL/min per 1.73 m 2 ) or high (≥60 mL/min per 1.73 m 2 )
Statistical Analyses
Data were analyzed using STATA/SE. To adjust for seasonal variation in plasma 25-hydroxyvitamin D levels, we assigned individuals to percentiles of plasma 25-hydroxyvitamin D concentration by month of sample collection. Participants were grouped according to plasma 25-hydroxyvitamin D levels into the upper 2 quartiles (the 50th-100th percentile; interquartile range within group, 47-71 nmol/L) as reference group to achieve a large group representative of the population, the second quartile as an intermediate group (the 25th-49th percentile; 28-46 nmol/L), and the first quartile (1st-24th percentile; 14-23 nmol/L); to explore the association with very low levels, we further divided the first quartile into the 10th-24th percentile (18-26 nmol/L), the 9th-5th percentile (13-17 nmol/L), and the 1st-4th percentile (7.5-12 nmol/L). We also assigned categories of plasma 25-hydroxyvitamin D concentrations according to widely used clinical cut points 30 : severe vitamin D deficiency as plasma 25-hydroxyvitamin D <25.0 nmol/L (<10.0 ng/mL); moderate vitamin D deficiency as 25.0-49.9 nmol/L (10.0-19.9 ng/mL); vitamin D insufficiency as 50.0-74.9 nmol/L (20.0-29.9 ng/mL); and optimal vitamin D range as ≥75.0 nmol/L (≥30.0 ng/mL).
We plotted cumulative incidence of ischemic heart disease and myocardial infarction, and survival against age using the Kaplan-Meier method and used log-rank trend tests across percentile groups of plasma 25-hydroxyvitamin D levels. We used Cox proportional hazard regression models with age as a time scale and use of left truncation (delayed entry), which implies that age is automatically adjusted for, to examine the association between plasma 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death. Multivariable Cox regression analyses included adjustment for sex, physical activity (9 categories, see Table I in the online-only Data Supplement), smoking (current/ former/never), diabetes mellitus (yes/no) as categorical variables and age, body mass index, pack-years smoked, alcohol consumption, plasma total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, and estimated glomerular filtration rate as continuous variables. For analyses using clinical categories, multivariable analyses additionally adjusted for month of blood draw, whereas for analysis using percentile categories month of blood draw is automatically adjusted for as percentiles were assigned for each month separately. We tested the assumption of proportional hazards by plotting −ln (survival probability) against ln (analysis time), and by the use of Schoenfeld global test; we did not detect major violations of this assumption. Interaction between plasma 25-hydroxyvitamin D levels and other covariates on the end points studied was evaluated by including 2-factor interaction terms, one at a time, in the multivariable Cox regression model.
Meta-Analyses
To summarize results from present and previous studies, we identified relevant peer-reviewed population-based prospective studies on the association between plasma 25-hydroxyvitamin D levels and risk of ischemic heart disease and early death by scanning relevant reference lists and by an electronic search of published work in PubMed up until January 2012, restricted to studies using immunochemistry or mass spectrometry for 25-hydroxyvitamin D measurements, using combinations of the following MeSH key words for ischemic heart disease: (vitamin D or 25-hydroxyvitamin or 25-hydroxyvitamin D or serum 25-hydroxyvitamin D or 25-hydroxyvitamin d3 or vitamin d3) and (cohort study or cohort studies or prospective cohort study or longitudinal study or observational study or prospective cohort or prospective studies or population study) and (cardiovascular disease or CVD or ischemic heart disease or IHD or acute myocardial infarct or acute myocardial infarction or myocardial infarction or MI or coronary heart disease or CHD or coronary artery disease or coronary syndrome or CAD or angina or stable angina pectoris or unstable angina or acute coronary syndrome or angina pectoris) and for early death: (vitamin D or 25-hydroxyvitamin or 25-hydroxyvitamin D or serum 25-hydroxyvitamin d or 25-hydroxyvitamin d3 or vitamin d3) and (cohort study or cohort studies or prospective cohort study or longitudinal study or observational study or prospective cohort or prospective studies or population study) and (death or mortality or allcause mortality or all cause mortality or total mortality or total death or all cause death). Studies were excluded if the study cohort comprised a smaller population subgroup or a patient population. This search strategy identified 17 studies on ischemic heart disease [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and 16 on early death. 3-6,8,10,12,17-24 P.B.J. and M.B. independently agreed on the articles included in the meta-analyses.
To compare risk estimates from the different studies, we estimated the log hazard ratio, β, of the risk between the lowest versus the highest quartile group of plasma 25-hydroxyvitamin D levels in the studies, assuming a log-linear association with the end point over the midrange of baseline values of plasma 25-hydroxyvitamin D. 31 SEs were calculated from the approximation: s 2 =2.54×(1/n 1 + 1/n 2 ), where n 1 is the number of events and n 2 is the number of disease-free participants. Meta-analyses were performed using random and fixed effect models. Risk was estimated overall and stratified in whites and mixed ethnicity and in level of vitamin D fortification of food in different countries: we divided studies into 3 categories of vitamin D fortification (none/limited fortification, European level of fortification, and American level of fortification) based on information at the time of sampling and geographic location of the study cohort ( Table II in the online-only Data Supplement). In United States fortification with vitamin D began earlier, is at a higher level, and in several more food products than in European countries where the start year and level of fortification differ from country to country as harmonized rules first became implemented in 2006 in the European Union. 32 Publication bias was evaluated by funnel plots, Begg rank correlation test, and Egger regression test. Heterogeneity was evaluated by I 2 statistics, with 95% CI based on Q-statistics. 33 
Results

The Copenhagen City Heart Study
The categories of plasma 25-hydroxyvitamin D levels. During follow-up, 3100 events of ischemic heart disease, 1625 events of myocardial infarction, and 6747 deaths occurred. Seasonal variation in plasma 25-hydroxyvitamin D levels is shown in Figure 1 . The highest median plasma 25-hydroxyvitamin D level of 57 nmol/L was observed in September and the lowest median level of 32 nmol/L in February. Cumulative incidence of ischemic heart disease and myocardial infarction as a function of age increased stepwise with stepwise decreasing levels of plasma 25-hydroxyvitamin D (log-rank trend, P=6×10 -15 and P=2×10 -20 ; Figure 2 ). For early death, the corresponding survival as a function of age decreased with decreasing levels of plasma 25-hydroxyvitamin D (log-rank trend, P=2×10 -45 ).
Stepwise decreasing plasma 25-hydroxyvitamin D levels were associated with stepwise increased risk of ischemic heart disease, myocardial infarction, and early death, both as a function of seasonally adjusted percentile categories and as a function of clinical categories (Figure 3 ; P for trend, 3×10 -2 -3×10 -53 ). Comparing individuals with plasma 25-hydroxyvitamin D levels in the 1st to 4th percentile (interquartile range, 7.5-12 nmol/L) with individuals with plasma 25-hydroxyvitamin D levels at the 50th-100th percentile (47-71 nmol/L), age and sex adjusted risk was increased by 72% (95% CI, 45%-104%) for ischemic heart disease, by 99% (60%-149%) for myocardial infarction, by 88% (70%-109%) for early death (Figure 3 ), and by 122% (80%-173%) for fatal ischemic heart disease/myocardial infarction (Figure 4 ). Corresponding increases after multivariable adjustment for potential confounders, including sex, physical activity, smoking, and diabetes mellitus as categorical variables and age, body mass index, pack-years smoked, alcohol consumption, plasma total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, and estimated glomerular filtration rate as continuous variables were 40% (14%-72%) for ischemic heart disease, 64% (25%-114%) for myocardial infarction, 57% (38%-78%) for early death (Figure 3 ), and 81% (40%-135%) for fatal ischemic heart disease/myocardial infarction ( Figure  4 ). Similar but attenuated results were seen for the clinical categories for all end points (Figures 3 and 4 ). Low 25-hydroxyvitamin D was not associated with nonfatal ischemic heart disease or nonfatal myocardial infarction (Figure 4) .
In stratified analyses, individuals in the 1st-9th percentile versus 50th-100th percentile of 25-hydroxyvitamin D 
6×10 -14
Hazard ratio levels had increased risk of ischemic heart disease, myocardial infarction, and early death in most strata of other covariates ( Figure I in the online-only Data Supplement). In accordance with this, tests of interaction between plasma 25-hydroxyvitamin D percentiles and other covariates on the 3 end points studied showed no evidence for interaction for most stratifications. However, we cannot completely rule out interaction between 25-hydroxyvitamin D levels and age on risk of early death ( Figure I in the online-only Data Supplement).
Meta-Analyses
In a meta-analysis including 18 general population studies with a total of 82 982 participants and 8376 ischemic heart disease events, risk of ischemic heart disease comparing the lowest versus the highest quartile of plasma 25-hydroxyvitamin D levels was increased by 39% (95% CI, 25%-54%, random effect) and 33% (28%-38%, fixed effect) ( Figure 5) ; there was no evidence of publication bias ( Figure II in the online-only Data Supplement). When the meta-analysis stratified in whites only versus mixed races, or in populations with fortification of food in none/limited, European levels versus American levels, reduced 25-hydroxyvitamin D levels associated with increased risk of ischemic heart disease in all strata and in both random and fixed effect models. In a meta-analysis including 17 general population studies with a total of 77 155 participants and 15 447 deaths, the corresponding risk of early death was increased by 46% (31%-64%, random effect) and by 35% (30%-42%, fixed effect) ( Figure 6 ); there was no evidence of publication bias ( Figure  III in the online-only Data Supplement). When the metaanalysis stratified in whites only versus mixed races, or in populations with fortification of food in none/limited, European levels versus American levels, reduced 25-hydroxyvitamin D levels associated with increased risk of early death in all strata and in both random and fixed effect models.
Discussion
In the highest powered general population study ever, we observed stepwise increases in risk of ischemic heart disease, myocardial infarction, and early death with stepwise decreasing plasma 25-hydroxyvitamin D levels. These findings were substantiated in the meta-analyses, where the present study contributed 37% of all ischemic heart disease events and 44% of all deaths and possibly used the most viable measurement method. 6  9  5  10  6  7  10  7  8  12  13  4  10  12  27  7  9  1  21   Ethnicity,  % whites  100  100  99  88  100  100  100  65  100  100  100  91  95  100  100  87  73  86  100   Sex,  % women  51  51  100  100  62  26  57  0  55  60  0  0  0  61  55  56  54  75  56   Mean age  at entry, yr  70  62  74  66  74  74  79  74  59  57  71  76  64  60  49  73  45  67  57 Weight % Hazard ratio, (95% CI) 5 The biological mechanism driving the relationship between reduced vitamin D levels and increased risk of cardiovascular disease and early death is not fully understood. The simplest chain of events could be that low vitamin D levels lead to increased renin gene transcription causing hypertension followed by development of atherosclerosis and eventually ischemic heart disease, myocardial infarction, and early death. However, several other consequences of low vitamin D levels like increased parathyroid hormone release, inflammation, proliferation of vascular smooth muscle cells, insulin resistance, thrombogenicity, dyslipidemia, and progressive extracellular matrix remodeling are all plausible in explaining part or all of the associations between low vitamin D levels and increased risk of ischemic heart disease, myocardial infarction, and early death. 34 Low physcial performance has been suggested to be associated with low levels of 25-hydroxyvitamin D 35 ; however, in the present study physical activity and 25-hydroxyvitamin D levels did not interact on risk of ischemic heart disease or on risk of early death. Finally, the present novel observation that low 25-hydroxyvitamin D levels particularly associated with increased risk of fatal ischemic heart disease and myocardial infarction, and not with nonfatal disease, points toward the possibility that low 25-hydroxyvitamin D levels simply is a marker of poor health in general.
Author/Study name if any
Another novel finding of the present study was that reduced 25-hydroxyvitamin D levels associated with increased risk of ischemic heart disease and early death irrespectively of levels of vitamin D fortification in food in the different countries. Despite large heterogeneity among studies in our metaanalyses and moderate to large heterogeneity in previous smaller meta-analyses, [36] [37] [38] previous findings are in agreement with our findings of low plasma 25-hydroxyvitamin D levels being associated with increased risk of ischemic heart disease and early death. The association between reduced plasma 25-hydroxyvitamin D levels and increased risk of cardiovascular disease and early death is indeed robust, as we observed stepwise increases in risks across 5 percentile categories and across 4 clinical categories.
Strengths of our study include the large prospective sample from a homogenous general population recruited from a limited geographic area with detailed information on several potential confounders, a high participation rate, long followup time with no loss to follow-up, high numbers of events, and the use of well-validated registry-based diagnoses and mortality data. Because participants were enrolled and blood samples drawn during 1981 to 1983, when focus on vitamin D supplementation or dietary intake was very limited, our data are for practical purposes free of confounding by these factors. Also, even today food in Denmark is largely free from vitamin D fortification.
Potential limitations include that some degradation of plasma 25-hydroxyvitamin D during almost 30 years of storage at −20°C may have occurred; however, such potential degradation is unlikely to have affected the results of the present study to a large extent for the following reasons. First, 25-hydroxyvitamin D has been observed to be minimally degradable during storage at -20°C. 39 Also, the mean plasma 25-hydroxyvitamin D concentration of 44 nmol/L in our study was similar to the values in the Mini-Finland Health Survey (43 nmol/L) and in the Aging in the Chianti Area (InCHIANTI) Study (40 nmol/L). Another potential limitation is selection bias, which is also unlikely to have affected the results in the present study to a large degree, as we randomly selected participants from the general population. Also, as plasma 25-hydroxyvitamin D levels differ between people with different skin color and depend on the amount of sun exposure, our results may not necessarily apply to all people, but certainly would be applicable to other populations with similar skin color and living in countries with similar sun exposure as in Northern Europe. Finally, another limitation regarding the meta-analyses is that the use of log hazard between lowest and highest quartile omits valuable data on the level of potential cut points for clinical use.
In conclusion, we observed a stepwise increase in risk of ischemic heart disease, myocardial infarction, and early death with stepwise decreasing levels of plasma 25-hydroxyvitamin D. These findings were substantiated in meta-analyses and were independent of the extent of vitamin D fortification of food.
